706 related articles for article (PubMed ID: 18356456)
1. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
2. Nephrogenic systemic fibrosis: possible association with a predisposing infection.
Golding LP; Provenzale JM
AJR Am J Roentgenol; 2008 Apr; 190(4):1069-75. PubMed ID: 18356457
[TBL] [Abstract][Full Text] [Related]
3. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
[TBL] [Abstract][Full Text] [Related]
5. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
Abraham JL; Thakral C; Skov L; Rossen K; Marckmann P
Br J Dermatol; 2008 Feb; 158(2):273-80. PubMed ID: 18067485
[TBL] [Abstract][Full Text] [Related]
6. Nephrogenic systemic fibrosis: center case review.
Lauenstein TC; Salman K; Morreira R; Tata S; Tudorascu D; Baramidze G; Singh-Parker S; Martin DR
J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
[TBL] [Abstract][Full Text] [Related]
7. Nephrogenic systemic fibrosis: a report of 29 cases.
Shabana WM; Cohan RH; Ellis JH; Hussain HK; Francis IR; Su LD; Mukherji SK; Swartz RD
AJR Am J Roentgenol; 2008 Mar; 190(3):736-41. PubMed ID: 18287446
[TBL] [Abstract][Full Text] [Related]
8. Nephrogenic systemic fibrosis: risk factors and incidence estimation.
Sadowski EA; Bennett LK; Chan MR; Wentland AL; Garrett AL; Garrett RW; Djamali A
Radiology; 2007 Apr; 243(1):148-57. PubMed ID: 17267695
[TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J
Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
[TBL] [Abstract][Full Text] [Related]
11. Incidence of nephrogenic systemic fibrosis at two large medical centers.
Prince MR; Zhang H; Morris M; MacGregor JL; Grossman ME; Silberzweig J; DeLapaz RL; Lee HJ; Magro CM; Valeri AM
Radiology; 2008 Sep; 248(3):807-16. PubMed ID: 18710976
[TBL] [Abstract][Full Text] [Related]
12. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
[TBL] [Abstract][Full Text] [Related]
13. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
Becker S; Walter S; Witzke O; Kreuter A; Kribben A; Mitchell A
Nephron Clin Pract; 2012; 121(1-2):c91-4. PubMed ID: 23182840
[TBL] [Abstract][Full Text] [Related]
14. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities.
Wertman R; Altun E; Martin DR; Mitchell DG; Leyendecker JR; O'Malley RB; Parsons DJ; Fuller ER; Semelka RC
Radiology; 2008 Sep; 248(3):799-806. PubMed ID: 18632533
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan).
Khurana A; Runge VM; Narayanan M; Greene JF; Nickel AE
Invest Radiol; 2007 Feb; 42(2):139-45. PubMed ID: 17220732
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
Rydahl C; Thomsen HS; Marckmann P
Invest Radiol; 2008 Feb; 43(2):141-4. PubMed ID: 18197066
[TBL] [Abstract][Full Text] [Related]
17. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review.
Sanyal S; Marckmann P; Scherer S; Abraham JL
Nephrol Dial Transplant; 2011 Nov; 26(11):3616-26. PubMed ID: 21441397
[TBL] [Abstract][Full Text] [Related]
18. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?
Singh M; Davenport A; Clatworthy I; Lewin J; Deroide F; Hubbard V; Rustin MH
Br J Dermatol; 2008 Jun; 158(6):1358-62. PubMed ID: 18363754
[TBL] [Abstract][Full Text] [Related]
19. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.
Collidge TA; Thomson PC; Mark PB; Traynor JP; Jardine AG; Morris ST; Simpson K; Roditi GH
Radiology; 2007 Oct; 245(1):168-75. PubMed ID: 17704357
[TBL] [Abstract][Full Text] [Related]
20. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors.
Khurana A; Greene JF; High WA
J Am Acad Dermatol; 2008 Aug; 59(2):218-24. PubMed ID: 18538448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]